Sr One Capital Management, LLC bought $27M of ADRX
owner at ADARx Pharmaceuticals, Inc.. 1,600,000 shares at an average of $17.00, traded Sep 28, 2026, filed Sep 29, 2026.
Score components
- +12Role10% owner
- +25Trade size$27.2M at market
- +6Relative to holdingsHoldings up 32%
- 0Price contextNo price history yet
- +15Cluster5 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-408064, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 28, 2026 | CConversion Common Stockindirect: See Note 2 | +3,334,938 | - | - | 3,334,938 | 13 d ago |
| Sep 28, 2026 | CConversion Common Stockindirect: See Note 2 | +1,113,666 | - | - | 4,448,604 | 13 d ago |
| Sep 28, 2026 | CConversion Common Stockindirect: See Note 2 | +512,897 | - | - | 4,961,501 | 13 d ago |
| Sep 28, 2026 | POpen-market purchase Common Stockindirect: See Note 2 | +592,593 | $17.00 | $10M | 5,554,094 | 13 d ago |
| Sep 28, 2026 | CConversion Common Stockindirect: See Note 3 | +1,538,691 | - | - | 1,538,691 | 13 d ago |
| Sep 28, 2026 | POpen-market purchase Common Stockindirect: See Note 3 | +414,814 | $17.00 | $7.1M | 1,953,505 | 13 d ago |
| Sep 28, 2026 | CConversion Common Stockindirect: See Note 4 | +1,667,468 | - | - | 1,667,468 | 13 d ago |
| Sep 28, 2026 | CConversion Common Stockindirect: See Note 4 | +169,001 | - | - | 1,836,469 | 13 d ago |
| Sep 28, 2026 | POpen-market purchase Common Stockindirect: See Note 5 | +592,593 | $17.00 | $10M | 592,593 | 13 d ago |
| Sep 28, 2026 | CConversion Series B Preferred Stockderivativeindirect: See Note 2 | -3,907,547 | $0.00 | $0 | 0 | 13 d ago |
| Sep 28, 2026 | CConversion Series B-1 Preferred Stockderivativeindirect: See Note 2 | -1,304,883 | $0.00 | $0 | 0 | 13 d ago |
| Sep 28, 2026 | CConversion Series C Preferred Stockderivativeindirect: See Note 2 | -600,962 | $0.00 | $0 | 0 | 13 d ago |
| Sep 28, 2026 | CConversion Series C Preferred Stockderivativeindirect: See Note 3 | -1,802,885 | $0.00 | $0 | 0 | 13 d ago |
| Sep 28, 2026 | CConversion Series B Preferred Stockderivativeindirect: See Note 4 | -1,953,773 | $0.00 | $0 | 0 | 13 d ago |
| Sep 28, 2026 | CConversion Series B-1 Preferred Stockderivativeindirect: See Note 4 | -198,019 | $0.00 | $0 | 0 | 13 d ago |
Related signals
Other insiders at ADARx Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 58Moderate | ADARx Pharmaceuticals, Inc. | Orbimed Advisors LLC director, owner | $16M 950,000 shares | +7% | |
| 58Moderate | ADARx Pharmaceuticals, Inc. | Carl L Gordon director, owner | $16M 950,000 shares | +7% | |
| 50Moderate | ADARx Pharmaceuticals, Inc. | Erez Chimovits director | $1.0M 61,516 shares | +1% | |
| 61Notable | ADARx Pharmaceuticals, Inc. | Simeon George director, owner | $27M 1,600,000 shares | +32% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.